Key Account Manager - Mobile Surgery Solutions
About the job
- At least 5 years of capital equipment sales experience selling directly into operating rooms and radiology.
- Demonstrated solution-selling and execution skills in a complex team-selling environment.
- A Bachelor of Science or Bachelor of Arts degree in a related discipline, or equivalent experience.
- Ability to successfully perform the minimum physical, cognitive, and environmental requirements for the sales position, with or without accommodation.
- Ability to travel in the Maryland, West Virginia, and Pittsburgh area.
- U.S. work authorization is required; the company will not consider candidates who require sponsorship for a work-authorized visa now or in the future.
- Must reside in or within commuting distance to Baltimore, Maryland, or Pittsburgh, Pennsylvania.
- Serve as the primary point of contact for Mobile Surgery decision-makers inside and outside hospitals.
- Identify, develop, and close Mobile Surgery opportunities in Philips-installed, competitively installed, and new-construction laboratories and operating rooms.
- Collaborate with Cardiovascular Fixed System Account Managers, Interventional Guided Therapy Devices, Cardiovascular Ultrasound, Enterprise Diagnostic Informatics in Cardiology, Out of Hospital Business Development, Precision Diagnosis, Connected Care Patient Monitoring, Account Executives, Specialists, Services, and Solutions teams.
- Establish territory growth plans and strategic initiatives and translate them into clear objectives and targets.
- Develop and continually refine business strategies for key accounts, customers, and the territory to achieve sales targets based on the competitive landscape, business models, product features, service offerings, and positioning.
- Document the territory install base for represented solutions and establish plans to address all assigned accounts, including breakthrough competitive accounts, segment strategy, and market potential.
- Drive the sales process by uncovering compelling customer events, engaging stakeholders, developing coaches, executing C-Arm demonstrations, and escalating as appropriate.
- Establish and maintain effective relationships with external and internal customers by delivering customer-centric solutions based on customer needs and pain points.
About the company
Philips Respironics designs sleep and respiratory care devices, including CPAP and BiPAP machines, ventilators, and oxygen concentrators, plus related systems. These devices deliver regulated air pressure, support or assist breathing, and provide concentrated oxygen, often paired with software and data tools for monitoring. The division differentiates itself through its long history within Philips and its integrated ecosystem that connects devices with analytics and clinical support across hospital, clinic, and home settings. Its goal is to improve quality of life and clinical outcomes for people with sleep and respiratory conditions by offering reliable devices, patient support, and data-driven care.
Company Size
N/A
Company Stage
Acquired
Total Funding
$164.7M
Headquarters
Murrysville, Pennsylvania
Founded
1891
Simplify's Take
What believers are saying
- More than 99% of registered CPAP and BiPAP recalls were remediated globally by December 2025.
- Philips reported Q1 2026 connected care growth and reiterated full-year guidance in May.
- Respironics-related charges fell to EUR 209 million in 2025 after major settlements finalized.
What critics are saying
- FDA consent decree still bars new U.S. CPAP and BiPAP sales in 2026.
- Repeated FDA noncompliance can keep Philips Respironics locked out of the U.S. market indefinitely.
- The 2021 recall remains active; ventilator remediation and lawsuits keep liability and scrutiny alive.
What makes Philips unique
- Philips Respironics services recalled U.S. devices and sells parts under the 2024 consent decree.
- Outside the U.S., Philips Respironics still sells sleep and respiratory devices in 2026.
- Its 15-million-device installed base gives it unmatched service reach and replacement leverage.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.